Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye
Information source: Hospital Governador Celso Ramos
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Blind Painful Eye; Refractory Glaucoma; Control of Pain Through Drug Injection
Intervention: Triamcinolone (Drug); Chlorpromazine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Hospital Governador Celso Ramos Official(s) and/or principal investigator(s): Deborah C Ribas, MD, Principal Investigator, Affiliation: Hospital Governador Celso Ramos
Summary
The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and
retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes.
Clinical Details
Official title: Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye
Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Primary outcome: Changes in Pain intensity
Secondary outcome: Changes in Use of eyedrops before and after drug injectionChanges in Intraocular pressure (IOP)
Detailed description:
The management of chronic eye pain is a constant challenge to ophthalmology. Treatment
varies with the intensity of pain, and topical eye drops and contact lens therapy are
effective in many patients. In refractory cases, and without vision, surgical removal of the
eye through enucleation is considered classical therapy. As less invasive alternatives we
have cyclodestruction and neurolytic drug injection in order to promote analgesia for a
prolonged period.
The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and
retrobulbar chlorpromazine as alternatives in the management of This is a prospective study
of patients with blind painful eyes not responsive to topical treatment and with no
indication for evisceration seen at the Department of Ophthalmology, Hospital Governador
Celso Ramos (HGCR) in 2010.
Eligibility
Minimum age: 15 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients treated in the period at HGCR who wanted to be part of the protocol by
signing the consent form
Exclusion Criteria:
- patients whose follow-up period was less than three months
Locations and Contacts
Hospital Governador Celso Ramos, Florianopolis, Santa Catarina 88015270, Brazil
Additional Information
Starting date: January 2010
Last updated: July 27, 2011
|